Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry, Uppsala University, BMC, Box 574, SE-751 23 Uppsala, Sweden.
Bioorg Med Chem. 2010 Jul 15;18(14):5413-24. doi: 10.1016/j.bmc.2010.05.027. Epub 2010 May 20.
Phenylglycine has proved to be a useful P2 residue in HCV NS3 protease inhibitors. A novel pi-pi-interaction between the phenylglycine and the catalytic H57 residue of the protease is postulated. We hypothesized that the introduction of a vinyl on the phenylglycine might strengthen this pi-pi-interaction. Thus, herein is presented the synthesis and inhibitory potency of a series of acyclic vinylated phenylglycine-based HCV NS3 protease inhibitors. Surprisingly, inhibitors based on both D- and L-phenylglycine were found to be effective inhibitors, with a slight preference for the d-epimers. Furthermore, prime-side alkenylic extension of the C-terminal acylsulfonamide group gave significantly improved inhibitors with potencies in the nanomolar range (approximately 35 nM), potencies which were retained on mutant variants of the protease.
苯甘氨酸已被证明是 HCV NS3 蛋白酶抑制剂中有用的 P2 残基。假定苯甘氨酸与蛋白酶的催化 H57 残基之间存在新的π-π相互作用。我们假设在苯甘氨酸上引入乙烯基可能会增强这种π-π相互作用。因此,本文介绍了一系列非环乙烯基苯甘氨酸基 HCV NS3 蛋白酶抑制剂的合成和抑制效力。令人惊讶的是,基于 D-和 L-苯甘氨酸的抑制剂均被发现是有效的抑制剂,其中 d-差向异构体略有优势。此外,C 末端酰基磺酰胺基团的前位烯丙基扩展给出了显著改善的抑制剂,其效力在纳摩尔范围内(约 35 nM),并且在蛋白酶的突变变体上保留了效力。